FindTrial
Sign In

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01852682
Enrollment
Unknown
Registered
2013-05-14
Start date
Unknown
Completion date
Unknown
Last updated
2014-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperphosphatemia, Peritoneal Dialysis

Keywords

Peritoneal Dialysis, Hyperphosphatemia

Brief summary

The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.

Interventions

DRUGPA21

Sponsors

Kissei Pharmaceutical Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum

Inclusion criteria

* Receiving stable maintenance peritoneal dialysis * Peritoneal dialysis patients with hyperphosphatemia

Exclusion criteria

* Patients having history of a pronounced brain / cardiovascular disorder * Patients having severe gastrointestinal disorders * Patients having severe hepatic disorders

Design outcomes

Primary

MeasureTime frame
Serum phosphate concentrations12 weeks

Secondary

MeasureTime frame
Incidences of Adverse Events12 weeks
Serum phosphate concentrations28 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026